Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $1.95 Million - $2.9 Million
-63,507 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$37.06 - $47.11 $984,276 - $1.25 Million
26,559 Added 71.88%
63,507 $2.7 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $1.49 Million - $2.12 Million
36,948 New
36,948 $1.64 Million
Q2 2021

Aug 10, 2021

SELL
$54.88 - $79.29 $922,368 - $1.33 Million
-16,807 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$70.65 - $96.76 $1.19 Million - $1.63 Million
16,807 New
16,807 $1.26 Million
Q1 2020

May 14, 2020

SELL
$26.15 - $77.24 $326,482 - $964,341
-12,485 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$60.18 - $154.77 $751,347 - $1.93 Million
12,485 New
12,485 $901,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Aviva PLC Portfolio

Follow Aviva PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.